magnetic resonance imaging |
515 |
musculoskeletal involvement |
515 |
sacroiliitis |
515 |
spondyloarthritis |
515 |
systemic sclerosis |
515 |
ankylosing spondylitis |
495, 468 |
beliefs about medicines |
495 |
illness perception |
495 |
medication adherence |
495 |
outcome measures |
468 |
quality of life |
468, 506 |
oral anticoagulant |
614 |
rheumatoid arthritis |
614, 600 |
spinal epidural hematoma |
614 |
tocilizumab |
614 |
abatacept |
618 |
monotherapy |
618 |
polymyositis |
618 |
fibromyalgia |
486, 506, 463, 584 |
musculoskeletal diseases |
486 |
widespread chronic pain |
486 |
work |
486 |
working females |
486 |
balneotherapy |
506 |
oxidative stress |
506 |
pain |
506, 463 |
calcitonin gene-related peptide |
463 |
receptor proteins |
463 |
chemokine (c-x-c motif) ligand 1 |
533 |
chemokine (c-x-c motif) ligand 2 |
533 |
interleukin-23 |
533 |
long non-coding ribonucleic acid |
533 |
messenger ribonucleic acid |
533 |
osteoclasts |
533 |
breast abscess |
623 |
immunoglobulin g4-related disease |
623 |
immunoglobulin g4-related mastitis |
623 |
autoimmunity |
545 |
cytokines |
545 |
inflammation |
545 |
phospho-camp response element binding |
545 |
signal transducer and activator of transcription 3 |
545 |
connective tissue diseases |
558 |
hypertension |
558 |
prognosis |
558 |
pulmonary |
558 |
rheumatic diseases |
558 |
systolic pulmonary artery pressure |
558 |
nailfold capillaroscopy |
568 |
raynaud’s phenomenon |
568 |
systemic lupus erythematosus |
568, 521 |
chronic widespread pain |
575 |
multicomponent |
575 |
multidisciplinary |
575 |
multimodal |
575 |
multiprofessional |
575 |
anxiety |
584 |
depression |
584 |
gustation |
584 |
olfaction |
584 |
bacteriuria |
592 |
infection |
592 |
sjögren’s syndrome |
592 |
urinary tract |
592 |
anti-tumor necrosis factor alpha |
600 |
japanese |
600 |
obesity |
600 |
remission |
600 |
behçet’s disease |
609 |
epidemiology |
609 |
familial mediterranean fever |
609 |
arthritis |
521 |
innate lymphoid cells |
521 |